Cover Image
市場調查報告書

皮膚、軟組織感染疾病:開發中產品分析

Skin And Soft Tissue Infections - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 257830
出版日期 內容資訊 英文 40 Pages
訂單完成後即時交付
價格
Back to Top
皮膚、軟組織感染疾病:開發中產品分析 Skin And Soft Tissue Infections - Pipeline Review, H2 2017
出版日期: 2017年07月25日 內容資訊: 英文 40 Pages
簡介

所謂皮膚、軟組織感染疾病,是指在皮膚層和其下的軟組織發病的感染疾病。皮膚產生刀傷、刮傷、咬傷等創傷,病毒、細菌、真菌由此侵入而發病。主要的症狀,有腫脹、腫包和發熱,皮膚的各處的皮疹,癤,癰等。在主要的風險要素,有皮膚的損傷和放射治療,血液循環不良的體液集積(水腫),心臟衰竭,肝病,過去的淋巴節摘出經歷,體重過多,慢性皮膚疾病(濕疹等)等。

本報告提供全球各國的皮膚、軟組織感染疾病治療用的開發中產品的開發情形相關分析,產品開發、上市的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊,為您概述為以下內容。

目錄

簡介

  • 分析範圍

皮膚、軟組織感染疾病概要

治療藥的開發

  • 皮膚、軟組織感染疾病開發中產品:概要
  • 皮膚、軟組織感染疾病開發中產品:各企業
  • 皮膚、軟組織治療藥:開發中的產品一覽:各企業

皮膚、軟組織:治療藥的評估

  • 各標的
  • 各作用機制
  • 各投藥法
  • 各分子類型

皮膚、軟組織開發治療藥的企業

  • Atox Bio Ltd
  • CorMedix Inc
  • Takeda Pharmaceutical Company Ltd
  • Valevia UK Ltd
  • Wockhardt Ltd

藥物簡介

皮膚、軟組織治療藥:開發暫停的產品

皮膚、軟組織相關產品的開發里程碑

  • 值得注意的最新趨勢、新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9581IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Skin And Soft Tissue Infections - Pipeline Review, H2 2017, provides an overview of the Skin And Soft Tissue Infections (Dermatology) pipeline landscape.

Skin and soft tissue infections are infections involving the layers of the skin and the soft tissues beneath it. Viruses, bacteria, and fungi generally cause skin and soft tissue infections by entering the body at a spot where a cut, scrape, bite, or other wound has broken the skin. Symptoms include swelling, warmth, and redness in a distinct area of skin, abscesses, furuncles and carbuncles. Risk factors include injury to the skin, radiation therapy, accumulation of fluid (edema) due to poor circulation, heart failure, liver disease, or past surgery to remove lymph nodes, being overweight and chronic skin conditions, such as eczema.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Skin And Soft Tissue Infections - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Skin And Soft Tissue Infections (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Skin And Soft Tissue Infections (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Skin And Soft Tissue Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 1, 3 and 1 respectively.

Skin And Soft Tissue Infections (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Skin And Soft Tissue Infections (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Skin And Soft Tissue Infections (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Skin And Soft Tissue Infections (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Skin And Soft Tissue Infections (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Skin And Soft Tissue Infections (Dermatology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Skin And Soft Tissue Infections (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Skin And Soft Tissue Infections (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Skin And Soft Tissue Infections - Overview
    • Skin And Soft Tissue Infections - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Skin And Soft Tissue Infections - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Skin And Soft Tissue Infections - Companies Involved in Therapeutics Development
    • Atox Bio Ltd
    • CorMedix Inc
    • Takeda Pharmaceutical Company Ltd
    • Valevia UK Ltd
    • Wockhardt Ltd
  • Skin And Soft Tissue Infections - Drug Profiles
    • ADEP-4 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • alalevonadifloxacin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ceftaroline fosamil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CRMD-004 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KBP-7072 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • reltecimod sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Skin and Soft Tissue Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VAL-301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Skin And Soft Tissue Infections - Dormant Projects
  • Skin And Soft Tissue Infections - Product Development Milestones
    • Featured News & Press Releases
      • May 23, 2017: Atox Bios Reltecimod Passes Futility Analysis in Phase 3 ACCUTE Study; Trial Continues as Planned
      • Nov 03, 2016: Atox Bio Announces Independent Safety Monitoring Committee Recommendation to Continue Phase 3 Study Of AB103 In Necrotizing Soft Tissue Infections
      • Jun 15, 2016: Atox Bio Awarded Next Milestone-based Option by BARDA to Support Development of AB103 for Necrotizing Soft Tissue Infections
      • Dec 07, 2015: Atox Bio Enrolls First Patient in Phase 3 Study of Potential Treatment for Necrotizing Soft Tissue Infection (Flesh Eating Bacteria)
      • Sep 29, 2014: Atox Bio Awarded Contract Worth up to $24 Million for the Development of AB103 by the Biomedical Advanced Research and Development Authority
      • Aug 05, 2014: AB103 Granted Orphan Medicinal Product Designation in the European Union for the Treatment of Necrotizing Soft Tissue Infections
      • Nov 20, 2012: Atox Bio Announces Positive Top-line Results In AB103 Necrotizing Soft Tissue Infections Phase IIa Trial
      • Sep 10, 2012: Atox Bio's AB103 Receives FDA Fast Track Designation For Treatment Of Necrotizing Soft Tissue Infections
      • Oct 25, 2011: Atox Bio Receives Orphan Drug Designation For AB103 For Treatment Of Necrotizing Soft Tissue Infections
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Skin And Soft Tissue Infections, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Skin And Soft Tissue Infections - Pipeline by Atox Bio Ltd, H2 2017
  • Skin And Soft Tissue Infections - Pipeline by CorMedix Inc, H2 2017
  • Skin And Soft Tissue Infections - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017
  • Skin And Soft Tissue Infections - Pipeline by Valevia UK Ltd, H2 2017
  • Skin And Soft Tissue Infections - Pipeline by Wockhardt Ltd, H2 2017
  • Skin And Soft Tissue Infections - Dormant Projects, H2 2017

List of Figures

  • Number of Products under Development for Skin And Soft Tissue Infections, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top